You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb)

Showing 1 - 25 of 9,876
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers Trial in New York (Humanized 3F8 Bispecific Antibody, Blood draw)

Terminated
  • Neuroblastoma
  • +2 more
  • Humanized 3F8 Bispecific Antibody
  • Blood draw
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 11, 2022

Recurrent Osteosarcoma Trial in Los Angeles, New York, Houston (humanized anti-GD2 antibody, GM-CSF)

Recruiting
  • Recurrent Osteosarcoma
  • humanized anti-GD2 antibody
  • GM-CSF
  • Los Angeles, California
  • +2 more
Dec 22, 2022

Melanoma, Neuroblastoma, Sarcoma Trial in New York (124I-Humanized 3F8)

Active, not recruiting
  • Melanoma
  • +2 more
  • 124I-Humanized 3F8
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Dec 1, 2022

Neuroblastoma Trial in New York (Hu3F8 With GM-CSF)

Active, not recruiting
  • Neuroblastoma
  • Hu3F8 With GM-CSF
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 2, 2022

Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)

Recruiting
  • Neuroblastoma
  • Naxitamab monotherapy
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 31, 2023

Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in Columbus (procedure, drug, biological)

Not yet recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • HER2-Negative Breast Carcinoma
  • Biospecimen Collection
  • +5 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 30, 2023

Neuroblastoma, High-Risk Trial in New York (cyclophosphamide, NK cells, hu3F8)

Active, not recruiting
  • Neuroblastoma
  • High-Risk
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 14, 2022

Neuroblastoma Trial in New York (Humanized 3F8 Monoclonal Antibody (Hu3F8))

Active, not recruiting
  • Neuroblastoma
  • Humanized 3F8 Monoclonal Antibody (Hu3F8)
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Aug 24, 2021

Neuroblastoma Trial in New York (Hu3F8, GM-CSF, Isotretinoin)

Active, not recruiting
  • Neuroblastoma
  • Hu3F8
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 1, 2022

Neuroblastoma Trial in New York (3F8 Monoclonal Antibody Combined with Interleukin-2)

Completed
  • Neuroblastoma
  • 3F8 Monoclonal Antibody Combined with Interleukin-2
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 26, 2021

Neuroblastoma Trial in New York (anti-GD2 murine IgG3 mAb 3F8)

Completed
Has Results
  • Neuroblastoma
  • anti-GD2 murine IgG3 monoclonal antibody 3F8
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Apr 21, 2022

Neuroblastoma Trial in New York (beta-glucan, mAb 3F8, immunohistochemistry staining method)

Completed
  • Neuroblastoma
  • beta-glucan
  • +3 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 4, 2022

Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma, Refractory Nodular

Not yet recruiting
  • Nodular Lymphocyte Predominant Hodgkin Lymphoma
  • +2 more
  • Biopsy
  • +9 more
  • (no location specified)
Jun 1, 2023

Brain and CNS Tumors, Intraocular Melanoma, Lung Cancer Trial in New York (genetic, other, radiation)

Active, not recruiting
  • Brain and Central Nervous System Tumors
  • +9 more
  • DNA analysis
  • +4 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 28, 2021

Neuroblastoma (NB) Trial in New York (Irinotecan, temozolomide, Hu3F8)

Active, not recruiting
  • Neuroblastoma (NB)
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 19, 2021

Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +4 more
  • Necitumumab
  • +4 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Jan 5, 2023

Neuroblastoma Trial in Worldwide (GM-CSF + Naxitamab)

Recruiting
  • Neuroblastoma
  • GM-CSF + Naxitamab
  • Gainesville, Florida
  • +22 more
Aug 29, 2022

Classic Hodgkin Lymphoma Trial (procedure, biological, drug, other, radiation)

Not yet recruiting
  • Classic Hodgkin Lymphoma
  • Biospecimen Collection
  • +19 more
  • (no location specified)
Jan 6, 2023

B Acute Lymphoblastic Leukemia Trial (procedure, biological, drug, radiation)

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • Biospecimen Collection
  • +19 more
  • (no location specified)
Nov 8, 2023

High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma Trial in Canada, United States (Dinutuximab,

Recruiting
  • High Risk Neuroblastoma
  • +4 more
  • Biospecimen Collection
  • +6 more
  • Los Angeles, California
  • +10 more
Jan 19, 2023

Mantle Cell Lymphoma Trial in United States (Acalabrutinib, Bortezomib, Cyclophosphamide)

Recruiting
  • Mantle Cell Lymphoma
  • New Orleans, Louisiana
  • +5 more
Dec 13, 2022

Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia Trial in

Terminated
Has Results
  • Philadelphia Chromosome Negative
  • +2 more
  • Blinatumomab
  • +11 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 3, 2022

HER2-Positive Solid Tumors Trial (Chort 1 of M802, Chort 2 of M802, Cohort 3 of M802)

Not yet recruiting
  • HER2-Positive Solid Tumors
  • Chort 1 of M802
  • +7 more
  • (no location specified)
Jul 28, 2021

Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid

Recruiting
  • Acute Lymphoblastic Leukemia in Remission
  • +11 more
  • Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 24, 2022

DLBCL Trial in Houston (Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 10, 2022